GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Earnings Power Value (EPV)

Icosavax (Icosavax) Earnings Power Value (EPV) : $4.42 (As of Sep23)


View and export this data going back to 2021. Start your Free Trial

What is Icosavax Earnings Power Value (EPV)?

As of Sep23, Icosavax's earnings power value is $4.42. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Icosavax Earnings Power Value (EPV) Historical Data

The historical data trend for Icosavax's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Earnings Power Value (EPV) Chart

Icosavax Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Earnings Power Value (EPV)
- - - -

Icosavax Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Icosavax's Earnings Power Value (EPV)

For the Biotechnology subindustry, Icosavax's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icosavax's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Icosavax's Earnings Power Value (EPV) falls into.



Icosavax Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.


Icosavax  (NAS:ICVX) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Icosavax Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Icosavax's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Icosavax (Icosavax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101
Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Executives
Adam K. Simpson director, officer: Chief Executive Officer C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan officer: Chief Medical Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley officer: Chief Business Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo officer: Chief Financial Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman officer: Chief Scientific Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan officer: EVP, Head of Research & Dev. C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu officer: See Remarks 1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson officer: See Remarks 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil director C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver director C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p. 10 percent owner GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807